Results 61 to 70 of about 5,406 (200)

Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting

, 2011
INTRODUCTION: Aprepitant is the only neurokinin (NK(1)) receptor antagonist (RA) approved for prevention of chemotherapy-induced nausea and vomiting (CINV). Aprepitant is co-administered with a 5-HT(3) RA and a corticosteroid. Although aprepitant is safe,
Herrstedt, Jørn, Ruhlmann, Christina H, Jørn Herrstedt, Christina H Ruhlmann   +3 more
core   +1 more source

Aprepitant antagonizes the SP effect on CD34⁺cells and CD68⁺MAC.

, 2020
(a) Quantitative analysis, and representative images of CD68 immunostainings in human skin fragments at day 0 or treated with vehicle, or SP, or aprepitant, or aprepitant and SP ex vivo.
Youhei Uchida (8351202), Jérémy Chéret (8351208), Jennifer Gherardini (8351199), Marta Bertolini (564966), Ralf Paus (261703), Jonathan A. Hardman (8351205), Kimberly Mace (3433709)   +6 more
core   +1 more source

The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant

, 2023
The substance P (SP)/neurokinin-1 receptor (NK-1R) system is involved in cancer progression. NK-1R, activated by SP, promotes tumor cell proliferation and migration, angiogenesis, the Warburg effect, and the prevention of apoptosis.
Rafael Coveñas, Miguel Muñoz, Prema Robinson, Francisco D. Rodríguez   +3 more
core   +1 more source

Efficacy of Aprepitant for Nausea in Patients with Head and Neck Cancer Receiving Daily Cisplatin Therapy [PDF]

, 2014
Background: Although efficacy of aprepitant for suppressing emesis associated with single-dose cisplatin has been demonstrated, there are limited data on the antiemetic effect of this oral neurokinin-1 receptor antagonist during daily administration of ...
Kaneko, Kenichi, Takano, Atsushi, Katsura, Motoyasu, Takahashi, Haruo, Yamaguchi, Nimpei, Ishimaru, Kotaro   +5 more
core   +2 more sources

Substance P and NK‐1R in Dengue: A First Serological Investigation

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Dengue fever lacks reliable biomarkers to explain its complex pathophysiology. Substance P (SP) and its receptor, the Neurokinin‐1 receptor (NK1R), known regulators of inflammation and vascular permeability in viral infections, may play a role in dengue but remain unexplored. Aim/Objective To investigate the levels of SP and NK1R in
Riffat Mehboob, Imran Shahid, Shahzad Ahmad, Noreen Sarwar, Akash John, Zeeshan Mehboob, Majid Almansouri, Waleed Badoghaish   +7 more
wiley   +1 more source

Assessing the impact of aprepitant and ondansetron on postoperative nausea and vomiting in orthognathic surgeries: a randomized controlled trial

BMC Anesthesiology, 2023
Background Postoperative nausea and vomiting (PONV) is a common side effect associated with general anesthesia. Both ondansetron and aprepitant been effectively used to prevent PONV.
Mostafa Alam, Alireza Shakeri, Ardeshir Khorsand, Karim Nasseri, Sadaf Nasseri   +4 more
doaj   +1 more source

Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK

Cancer Management and Research, 2013
Samantha Humphreys,1 James Pellissier,2 Alison Jones3 1Market Access Department, Merck Sharp and Dohme Ltd, Hoddesdon, Hertfordshire, UK; 2Health Economic Statistics, Merck Research Laboratories, Upper Gwynedd, PA, USA; 3Department of Medical Oncology ...
Humphreys S, Pellissier J, Jones A
doaj  

Every‐other‐day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the “Rete Ematologica Pugliese”

Cancer Medicine, 2020
Background Compared with older 5‐HT3 receptor antagonists, palonosetron requires fewer drug administrations to prevent chemotherapy‐induced nausea and vomiting (CINV) following multiple‐day chemotherapy.
Nicola Di Renzo, Lorella Melillo, Fernando Porretto, Michela Dargenio, Vincenzo Pavone, Domenico Pastore, Patrizio Mazza, Donato Mannina, Anxur Merenda, Nicola Cascavilla, Giuseppina Greco, Rosella Matera, Erminio Bonizzoni, Luigi Celio, Maurizio Musso   +14 more
doaj   +1 more source

Review of nutrition management of pediatric intestinal pseudo‐obstruction

Nutrition in Clinical Practice, Volume 41, Issue 4, Page 1048-1060, August 2026.
Abstract Chronic intestinal pseudo‐obstruction (CIPO) is a rare, heterogeneous, and debilitating disorder characterized by profound intestinal dysmotility and severe nutrition challenges. Its presentation resembles that of mechanical bowel obstruction, but CIPO occurs in the absence of luminal obstruction.
Senthilkumar Sankararaman, Raisa Rani James, Bushra El‐Amaireh, Andrea Adler, Kadakkal Radhakrishnan, Sujithra Velayuthan   +5 more
wiley   +1 more source

Antiemetic Studies on the NK1 Receptor Antagonist Aprepitant

, 2004
Aprepitant (Emend, Merck Inc., Whitehouse Station, NJ), a neurokin-1 (NK1) receptor antagonist, is a first-in-class agent approved for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV).
Harry Raftopoulos, John P. Stoutenburg
core   +1 more source